Bozitinib

Drug Profile

Bozitinib

Alternative Names: CBI-3103; CBT-101; PLB-1001

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Crown Bioscience
  • Developer Beijing Pearl Biotechnology; CBT Pharmaceuticals; Crown Bioscience
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 31 Aug 2017 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Metastatic disease) in USA (PO) (NCT03175224)
  • 14 Jun 2017 CBT Pharmaceuticals plans a phase I trial to evaluate the safety, pharmacokinetics and efficacy of CBT 101, in patients with Solid tumours (Late-stage disease) and c-MET dysregulation, in USA (PO, Capsule) (NCT03175224)
  • 04 Apr 2017 CBT Pharmaceuticals announces intention to submit IND application to US FDA for Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top